The company said its sales for Q2 2025 (ended June 28, 2025) were $771 million, up 9% as reported and 8% in constant currency from $709 million a year earlier.

1. 01

   The company said its sales for Q2 2025 (ended June 28, 2025) were $771 million, up 9% as reported and 8% in constant currency from $709 million a year earlier.

2. 02

   Waters said its diluted GAAP earnings per share for Q2 were $2.47, compared with $2.40 a year earlier, and its non-GAAP EPS rose 12% to $2.95, compared with $2.63 a year earlier.

3. 03

   The company reported that for Q2, constant currency growth was 4% for Instruments, 9% for Service and 16% for Chemistry, and Total Recurring grew 11%. By market, Pharmaceutical grew 11% and Industrial grew 6%, while Academic & Government declined 3%.

4. 04

   Waters said it is raising its full-year 2025 constant currency sales growth guidance to +5.5% to +7.5% and its non-GAAP EPS guidance to $12.95 to $13.05. It said it expects non-GAAP EPS for Q3 to be in the range of $3.15 to $3.25.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.